Major Adverse Cardiac Events in Patients With Moderate to Severe Renal Insufficiency Treated With First-Generation Drug-Eluting Stents

• Published in: The American journal of cardiology 2010-02, Vol.105 (3), p.293-296
• Main Authors: Sukhija, Rishi, MD, Aronow, Wilbert S., MD, Palaniswamy, Chandrasekar, MD, Singh, Tarunjit, MD, Sukhija, Rashmi, MD, Kalapatapu, Kumar, MD, Mohan, Diwakar, MD, Pucillo, Anthony L., MD, Sorbera, Carmine, MD, Kakar, Priyanka, MD, Weiss, Melvin B., MD, Lal, Purshotam, MD, Monsen, Craig E., MD
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biological and medical sciences; Cardiology; Cardiology. Vascular system; Cardiovascular; Cardiovascular disease; Cardiovascular Diseases - complications; Cardiovascular Diseases - therapy; Coronary Artery Disease - etiology; Coronary Artery Disease - therapy; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Male; Medical sciences; Middle Aged; Myocardial Infarction - etiology; Myocardial Infarction - therapy; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; Paclitaxel - administration & dosage; Regression analysis; Renal failure; Renal Insufficiency - complications; Retrospective Studies; Risk factors; Sirolimus - administration & dosage; Stents
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2009.09.031

No data are available comparing the long-term outcome of sirolimus-eluting stents (SESs) versus paclitaxel-eluting stents (PESs) in patients with moderate to severe renal insufficiency. The incidence of major adverse cardiac events (MACE), including death, myocardial infarction, and target vessel revascularization, during long-term follow-up were studied in patients with a glomerular filtration rate of